Aequus Pharmaceuticals Inc
🇨🇦XTSX.AQSCanadaHealthcare
PriceCA$0.000.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 0
- Medium: 2
- Low: 0
Current ratio: below the level we flag as a liquidity warning
Quick ratio: below the level we flag as a liquidity warning
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- Canada
Identity
- Exchange
- TSX Venture Exchange . XTSX
- Type
- Stock
- ISIN
- CA0076361033
- CUSIP
- 007636103
Company
- Employees
- 0
- Headquarters
- Vancouver, Canada
- Website
- https://www.aequuspharma.ca
Market
- Shares outstanding
- 132.6M
- Market cap
- CA$0
Highlights
No high and low reported for today's session.
No 52-week high and low are reported for this listing.
- Market cap
- CA$0
- EPS LTM
- -CA$0.01calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$815.03K+192.96%up year on year
- Net income
- -CA$1.64M+42.7%up year on year
- Gross margin
- 57.23%+242.08%up year on year
- Free cash flow
- -CA$443.32K+84.05%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.